Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00464646
Status:
COMPLETED
Last Update Posted:
2021-10-25
First Post:
2007-04-19
Brief Title:
Therapy With Bevacizumab BEV Epirubicin and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Sponsor:
NSABP Foundation Inc
Organization:
NSABP Foundation Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-05
Start Date Type:
None
Primary Completion Date:
2009-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-05
Completion Date Type:
ACTUAL
First Submit Date:
2007-04-19
First Submit QC Date:
April 19 2007
Study First Post Date:
2007-04-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2012-09-26
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-04
Last Update Post Date:
2021-10-25
Last Update Post Date Type:
ACTUAL